Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REAL 1: Somapacitan vs Placebo and Daily Somatropin in AGHD
NCT02229851Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2014
- Primary completion
- Apr 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of somapacitan in adult growth hormone deficiency (AGHD) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change in Truncal Fat Percentage at 87 weeks. Started Oct 2014; status: completed.
02
Drugs
somapacitan
03
Conditions
adult growth hormone deficiency (AGHD)
Beyond the preview
Go deeper on NCT02229851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02229851.